GENOSKIN

Discover how HypoSkin® is transforming immunogenicity testing, especially for injectables, by enabling studies in full-thickness human skin models that preserve native immune architecture and immune competence.

Unwanted immunogenicity often hides in early immune signals. With HypoSkin®, capture APC activation and immune-mediated inflammation in real human skin across multiple donors.

Don’t wait for clinical signals to uncover immune risk. HypoSkin® enables preclinical, human-relevant assessment of unwanted immunogenicity and early immunotoxicity in injectable candidates by reproducing human skin immune dynamics.

Stop guessing immune reactions. Test them in real human skin. HypoSkin® reproduces human immune dynamics to assess unwanted immunogenicity and early immunotoxicity in injectables.

A powerful way to measure immune activation risk before launch: HypoSkin® delivers human-relevant toxicity and immunogenicity insights for deliverable drugs.

🐒🐒Recent FDA draft guidance signals a shift away from routine long-term non-human primate studies for certain biologics, encouraging earlier use of well-justified, human-relevant methods. For injectable therapeutics, this reinforces the need for predictive models that capture local tolerance and immune activation more accurately than traditional in vivo approaches. Our new Toxicity Pilot Study helps developers: ➜ Assess local toxicity directly in human skin ➜ Detect early, unwanted immune activation via cytokine profiling ➜ Gain translational insight before advancing to larger toxicology programs This pilot offers a focused, data-driven entry point to more confident development. 🎁Special launch pricing available for studies signed before December 31. Request your study plan and quote https://bit.ly/48XOq1X